Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;20(4):341-347.
doi: 10.2450/2022.0276-21. Epub 2022 Jan 21.

Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)

Francesco Paciullo  1 , Emanuele Valeriani  2 , Angelo Porfidia  3 , Marcello Di Nisio  4 , Marco P Donadini  5 , Rossella Marcucci  6 , Domenico Prisco  6 , Carlo Cagini  7 , Paolo Gresele  1 , Walter Ageno  5
Affiliations

Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)

Francesco Paciullo et al. Blood Transfus. 2022 Jul.

Abstract

Retinal vein occlusion (RVO) represents a common cause of visual impairment and blindness. RVO may be associated with both local (e.g., hyperopia, glaucoma) and systemic (e.g., hypertension, diabetes, smoking, obesity, and dyslipidaemia) risk factors. The association with thrombophilia remains controversial. Data on the use of antithrombotic therapy for RVO are poor and inconsistent with most of the information being derived from observational studies. Here we provide a position statement from the Italian Society on Thrombosis and Haemostasis (SISET) to guide the clinical and therapeutic management of patients with RVO based on the available evidence and expert opinion.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

FP, EV, MPD, CC, and DP have nothing to disclose. AP reports personal fees from Bayer, Boehringer Inghelheim, Daiichi Sankyo, BMS-Pfizer, Novartis and Aspen, outside the submitted work. MDN reports personal fees from Bayer, Daiichi Sankyo, BMS-Pfizer, Leo Pharma, Sanofi, and Aspen, outside the submitted work; RM reports lecture fees and advisory board from Amgen, Sanofi, Werfen, Bayer, Daichii-Sankyo, Pfizer, Viatris; PG reports speaker’s fees outside the submitted work from; WA has received a research grant from Bayer to support a clinical study in patients with splanchnic vein thrombosis, received honoraria for participation at advisory boards from Bayer, Boehringer Inghelheim, Daiichi Sankyo, BMS/Pfizer, Sanofi, and Portola, and reports grants and personal fees from Bayer, and personal fees from BMS/Pfizer, Daiichi Sankyo, Sanofi, Aspen, Janssen, and Portola.

Figures

Figure 1
Figure 1
Therapeutic approach to manage patients with retinal vein occlusion (RVO) *Small and isolated retinal haemorrhage does not represent an absolute contraindication to antithrombotic treatment. Perform vitreal procedures at the trough levels of anticoagulant therapy, when indicated.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Prisco D, Marcucci R, Bertini L, et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med. 2002;13:163–9. - PubMed
    1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313–9. - PMC - PubMed
    1. Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9:010427. - PMC - PubMed
    1. Mikhaĭlova MA, Sizova MV, Shelankova AV. [Pathogenesis of retinal vein occlusions]. Vestn Oftalmol. 2014;130:88–92. - PubMed
    1. Garcia-Horton A, Al-Ani F, Lazo-Langner A. Retinal vein thrombosis: The Internist’s role in the etiologic and therapeutic management. Thromb Res. 2016;148:118–24. - PubMed

Substances